Bharat Biotech to lead human monoclonal antibodies venture Kumar Jeetendra | May 9, 2020 A task authorized by the Council of Scientific and Industrial Research (CSIR) to create human monoclonal antibodies as treatment for COVID-19 diseases will be driven by Bharat Biotech. Reporting this on Friday, the Hyderabad-based immunization maker said however endeavors were in progress for advancement of medications and antibodies for controlling the pandemic, they were moderate …
ICMR collaborates with Bharat Biotech Limited to create coronavirus immunization Kumar Jeetendra | May 9, 2020 Indian Council of Medical Research (ICMR) has joined forces with Bharat Biotech International Limited (BBIL) to build up a completely indigenous immunization for COVID-19, the summit wellbeing research body said on Saturday. The antibody will be created utilizing the infection strain disconnected at the ICMR’s National Institute of Virology (NIV), Pune, an announcement said. The …
Bharat Biotech, Thomas Jefferson University ties up to create antibody for Covid-19 Kumar Jeetendra | May 21, 2020 Antibody producer Bharat Biotech and Thomas Jefferson University of Philadelphia have marked a restrictive deal to build up another immunization contender for Covid-19. The epic immunization was created utilizing a current deactivated rabies antibody as a vehicle for coronavirus proteins. This immunization is known to create a solid invulnerable reaction and is affirmed for the …
ICMR affirms Covaxin dispatch likely by August 15, clinical preliminaries optimized Kumar Jeetendra | July 3, 2020 An ICMR representative has affirmed the credibility of a letter by ICMR Head that said the antibody preliminaries for Hyderabad-based Bharat Biotech’s COVID-19 immunization Covaxin have been optimized and that it could be propelled most recent by August 15. ICMR had on July 2 purportedly asked Bharat Biotech in an inner correspondence to quick track …
Bharat Biotech begins human preliminaries for Covaxin, India’s first COVID-19 antibody Kumar Jeetendra | July 14, 2020 Bharat Biotech has started human trials on its vaccine offender,’Covaxin’. Covaxin, being developed by the Hyderabad-based bio tech business and Indian Council of Medical Research (ICMR) is now India’s first native COVID-19 vaccine. Bharat Biotech had said that it really is trying to build up a preliminary capacity of 200 million vials of the vaccine. …
Preparations on for next phase of clinical trial of’Covaxin’ vaccine Kumar Jeetendra | August 31, 2020 Preparations are underway in a hospital here for the commencement of the second stage of human clinical trial of’Covaxin’,” India’s indigenous COVID-19 vaccine, officials said. “The Phase I of the trial is still continuing as we are planning for the beginning of the Stage II trial soon,” Dr E Venkata Rao, Principal Investigator of the …
Bharat Biotech States Covaxin generated Strong immune response in monkeys Kumar Jeetendra | September 12, 2020 Bharat Biotech announced its prospective COVID-19 vaccine — Covaxin — was discovered to generate strong immune responses in rhesus macaques or monkeys, preventing infection and disease even upon high levels of exposure to live SARS-CoV-2 virus. The Hyderabad-based firm said data from the study on primates substantiate the immunogenicity of the vaccine candidate. Covaxin developed …
Bharat Biotech set to create intranasal COVID-19 immunization: Here is everything you require to know Kumar Jeetendra | September 23, 2020 Bharat Biotech Place to Create intranasal COVID-19 vaccine: This is all you need to know Hyderabad-based Bharat Biotech announced on September 23 that it has collaborated with the Washington University School of Medicine to develop an intranasal COVID-19 vaccine. Here are seven things you need to know about the novel chimp-adenovirus vaccine candidate: Bharat Biotech …
Covid immunization: Bharat Biotech to utilize ViroVax’s adjuvant for Covaxin Kumar Jeetendra | October 5, 2020 Trials, will use adjuvant Alhydroxiquim-II to boost immune response and longer lasting immunity. The technology has been used under this licensing arrangement with US-based ViroVax. Adjuvant is used to boost the vaccine efficacy. Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated in the National Institute of Virology (NIV), Pune under …
Bharat Biotech requested to submit total phase 2 information of its COVID-19 antibody before ph 3 preliminary Kumar Jeetendra | October 10, 2020 According to officials, the Hyderabad-based vaccine manufacturer applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to run phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. The firm in its program said that the study would cover 28,500 subjects aged 18 years and above and would …
Emergency use SEC approval for Bharat Biotech Covaxin Kumar Jeetendra | January 2, 2021 The SEC has recommended Covaxin for emergency use authorisation (EUA), reported news agency ANI quoting government sources. The recommendation, together with rollout modalities, will be taken up from the Drug Controller General of India (DCGI) to get a final decision on the issue. The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) …
Bharat Biotech’s partner Ocugen looks for endorsement for Covaxin in Canada Kumar Jeetendra | July 16, 2021 Ocugen Inc., Bharat Biotech’s partner for USA and Canada for COVID-19 vaccine Covaxin has initiated a rolling submission to Health Canada for the jab, the US company said in a regulatory filing. The move follows the release by Bharat Biotech of Phase 3 clinical trial results, which demonstrated efficacy and safety in nearly 25,800 adults, …
